Early childhood RSV monoclonal antibody uptake data

An icon with data
NCIRS monitored administration of the RSV monoclonal antibody nirsevimab to infants and young children aged under 2 years as part of state- and territory-funded infant RSV immunisation programs in 2024 and 2025.
An icon with data